WEBSITE BSE:0 NSE: Inc. Year: 2012 Industry: e-Commerce My Bucket: Add Stock
Last updated: 15:43
No Notes Added Yet
Sat Kartar Shopping Limited (SKSL), incorporated on June 29, 2012, is an Indian Ayurveda-focused healthcare company headquartered in New Delhi. Initially offering a blend of Ayurvedic and spiritual products, the company streamlined its offerings in August 2023 to concentrate exclusively on Ayurveda, aiming to promote natural wellness solutions. SKSL operates on a Direct-to-Consumer (D2C) model, distributing its products through its website, third-party e-commerce platforms, television marketing, and digital channels like Google and Meta . Th...Read More
Sat Kartar Shopping Limited (SKSL), incorporated on June 29, 2012, is an Indian Ayurveda-focused healthcare company headquartered in New Delhi. Initially offering a blend of Ayurvedic and spiritual products, the company streamlined its offerings in August 2023 to concentrate exclusively on Ayurveda, aiming to promote natural wellness solutions. SKSL operates on a Direct-to-Consumer (D2C) model, distributing its products through its website, third-party e-commerce platforms, television marketing, and digital channels like Google and Meta . The company\'s product portfolio includes over 50 SKUs categorized into niche therapeutic areas addressing specific health issues and lifestyle-based solutions. Key products include Addiction Killer, Liv Muztang, Kaama Gold, Ayush 82 Aadved for diabetes and blood sugar management, and joint pain relief solutions . SKSL emphasizes in-house research and development, with a team comprising Bachelor of Ayurvedic Medicine and Surgery (BAMS) doctors who create specialized formulations, which are then produced by contract manufacturers. The company claims to have successfully conducted clinical trials for products like Liv Muztang, Dr. Piles Free, and Dr. Madhu Amrit, demonstrating product efficacy. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹313 Cr.
Stock P/E 31.9
P/B 6.1
Current Price ₹199
Book Value ₹ 32.7
Face Value 10
52W High ₹237.9
Dividend Yield 0%
52W Low ₹ 124
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Net Sales | 52 | 83 | 128 | 163 | |
| Other Income | 0 | 0 | 0 | 1 | |
| Total Income | 52 | 83 | 128 | 164 | |
| Total Expenditure | 50 | 78 | 118 | 149 | |
| Operating Profit | 3 | 5 | 10 | 15 | |
| Interest | 0 | 0 | 1 | 1 | |
| Depreciation | 1 | 1 | 1 | 1 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 2 | 3 | 9 | 13 | |
| Provision for Tax | 0 | 1 | 2 | 3 | |
| Profit After Tax | 1 | 3 | 6 | 10 | |
| Adjustments | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 1 | 3 | 6 | 10 | |
| Adjusted Earnings Per Share | 1.2 | 2.2 | 5.6 | 6.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 27% | 46% | 0% | 0% |
| Operating Profit CAGR | 50% | 71% | 0% | 0% |
| PAT CAGR | 67% | 115% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 31% | NA% | NA% | NA% |
| ROE Average | 32% | 85% | 109% | 109% |
| ROCE Average | 40% | 63% | 53% | 53% |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Shareholder's Funds | 1 | 3 | 9 | 52 |
| Minority's Interest | 0 | 0 | 0 | 0 |
| Borrowings | 6 | 2 | 1 | 2 |
| Other Non-Current Liabilities | -0 | -0 | -1 | -1 |
| Total Current Liabilities | 5 | 9 | 12 | 11 |
| Total Liabilities | 12 | 14 | 21 | 64 |
| Fixed Assets | 3 | 4 | 3 | 6 |
| Other Non-Current Assets | 2 | 4 | 7 | 2 |
| Total Current Assets | 7 | 6 | 12 | 56 |
| Total Assets | 12 | 14 | 21 | 64 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 1 | 1 | 3 |
| Cash Flow from Operating Activities | 2 | 8 | 7 | -5 |
| Cash Flow from Investing Activities | -1 | -4 | -3 | -0 |
| Cash Flow from Financing Activities | -1 | -5 | -3 | 34 |
| Net Cash Inflow / Outflow | 0 | -0 | 2 | 28 |
| Closing Cash & Cash Equivalent | 1 | 1 | 3 | 31 |
| # | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 1.24 | 2.24 | 5.63 | 6.23 |
| CEPS(Rs) | 1.88 | 3.41 | 6.81 | 7.06 |
| DPS(Rs) | 0 | 0 | 0.18 | 0.7 |
| Book NAV/Share(Rs) | 0.69 | 2.92 | 8.42 | 32.71 |
| Core EBITDA Margin(%) | 4.43 | 6.26 | 8.01 | 8.73 |
| EBIT Margin(%) | 3.79 | 4.73 | 7.12 | 8.4 |
| Pre Tax Margin(%) | 2.9 | 4.15 | 6.72 | 8.07 |
| PAT Margin (%) | 2.67 | 3.02 | 4.93 | 6.02 |
| Cash Profit Margin (%) | 4.07 | 4.61 | 5.97 | 6.82 |
| ROA(%) | 11.54 | 19.06 | 35.5 | 23 |
| ROE(%) | 180.42 | 123.96 | 99.24 | 32.22 |
| ROCE(%) | 22.04 | 49.2 | 99.92 | 39.89 |
| Receivable days | 0.66 | 0.4 | 3.42 | 9.28 |
| Inventory Days | 2.61 | 1.56 | 1.28 | 5.74 |
| Payable days | 165.45 | 185.57 | 180.64 | 203.79 |
| PER(x) | 0 | 0 | 0 | 24.39 |
| Price/Book(x) | 0 | 0 | 0 | 4.65 |
| Dividend Yield(%) | 0 | 0 | 0 | 0.46 |
| EV/Net Sales(x) | 0.15 | 0.05 | 0.02 | 1.32 |
| EV/Core EBITDA(x) | 2.89 | 0.73 | 0.2 | 14.32 |
| Net Sales Growth(%) | 0 | 59.81 | 54.16 | 27.37 |
| EBIT Growth(%) | 0 | 99.58 | 132.34 | 50.23 |
| PAT Growth(%) | 0 | 80.7 | 151.6 | 55.66 |
| EPS Growth(%) | 0 | 80.7 | 151.6 | 10.73 |
| Debt/Equity(x) | 10.6 | 1.15 | 0.19 | 0.11 |
| Current Ratio(x) | 1.27 | 0.71 | 1.01 | 4.92 |
| Quick Ratio(x) | 1.2 | 0.68 | 0.97 | 4.52 |
| Interest Cover(x) | 4.27 | 8.2 | 17.6 | 25.38 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0.02 |
| # | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Promoter | 63.34 | 63.43 | 63.62 |
| FII | 6.31 | 0.44 | 0.13 |
| DII | 3.11 | 3.1 | 2.26 |
| Public | 27.24 | 33.03 | 34 |
| Others | 0 | 0 | 0 |
| Total | 100 | 100 | 100 |
| # | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Promoter | 1 | 1 | 1 |
| FII | 0.1 | 0.01 | 0 |
| DII | 0.05 | 0.05 | 0.04 |
| Public | 0.43 | 0.52 | 0.54 |
| Others | 0 | 0 | 0 |
| Total | 1.57 | 1.57 | 1.57 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
